Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female children with hypochondroplasia defined by a disproportional short limb height and a X-ray evidence of shortening of the long bones and failure of increase in the interpedicular distance between lumbar vertebrae L1 and L5~* Result of genetic analysis for mutation of gene FGFR3 already known or ongoing analysis at the beginning of the study~* Chronological age greater than or equal to 3 years~* Height for chronological age less than or equal to - 2 SDS~* Bone age less than or equal to 11 years for girls and 13 years for boys~* A written informed consent at the beginning of the pre-treatment period must be obtained from the parent(s)/legal guardian(s). Children able to understand the trial should personally sign and date the written informed consent~Additional inclusion criteria for each study prolongation:~* Bone age at Month 36 or Month 60 is compatible with treatment prolongation according to investigator opinion~* Subject is still under r-hGH treatment with Saizen® at Month 36 or Month 60~* Height gain greater than or equal to + 1 SDS after the 2 first years of treatment for treatment prolongation at Month 36 and growth velocity greater than or equal to 5 centimeter (cm) per year, with bone age less than 14 years for females or less than 16 years for males for treatment prolongation at Month 60~* According to investigator opinion, gene mutations of the subjects are not in connection with observed side effects during the 3 or 5 first years of treatment~* An updated written informed consent must be obtained from the parent(s)/legal guardian(s) before the start of each study prolongation. Children able to understand the trial should personally sign and date the written informed consent~Exclusion Criteria:~* Turner's Syndrome in girls~* Active malignant neoplastic disease~* Severe congenital malformations~* Proliferative or preproliferative diabetic retinopathy~* Evidence of any progression or recurrence of an underlying intra-cranial space occupying lesion~* Severe psychomotor retardation~* Diabetes mellitus or history of significant glucose intolerance as defined by a fasting blood glucose greater than 6.4 millimole per liter (mmol/L)~* Known renal insufficiency as defined by serum creatinine level 1.0 milligram per deciliter (mg/dL) (88 micromole per liter \[mcmol/L\])~* Known hepatic disease as defined by elevated liver enzymes or total bilirubin (\* 2 Normal)~* Current congestive heart failure, untreated hypertension, serious chronic edema of any cause~* Chronic infectious disease~* History of intracranial hypertension with papilledema~* Previous or ongoing treatment with sex steroid therapy such as estrogens or testosterone~* Previous or ongoing treatment with any therapy that may directly influence growth, including Growth Hormone (GH), Growth Hormone Releasing Hormone (GHRH) and long duration corticosteroids therapy~* Known hypersensitivity to somatropin or any of the excipients~* Epiphyseal fusion~* Participation to any clinical study within the 30 days preceding study entry~* Pregnant females

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- r-hGH (Saizen®) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).